Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 8/20 | 0.61 |
| ▸ | KMO | O15229 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 6/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20546305 | 1.00 | CTSA (0.61) | CTSAKMOCTSLCTSSCTSK | |
| SCHEMBL7237272 | 0.86 | MKNK1 (0.54) | CTSAKMOSUCNR1MKNK1MKNK2 | |
| SCHEMBL20546132 | 0.84 | KMT2A (0.58) | CTSAKMT2ASMN1; SMN2 | |
| SCHEMBL20546130 | 0.84 | KMT2A (0.58) | CTSAKMT2ASMN1; SMN2 | |
| SCHEMBL30829068 | 0.84 | TBXAS1 (0.50) | CTSASMN1; SMN2 | |
| SCHEMBL157096 | 0.84 | TBXAS1 (0.50) | CTSASMN1; SMN2 | |
| SCHEMBL157097 | 0.84 | TBXAS1 (0.50) | CTSASMN1; SMN2 | |
| SCHEMBL5720941 | 0.84 | TBXAS1 (0.50) | CTSASMN1; SMN2 | |
| SCHEMBL20546126 | 0.83 | PIM2 (0.50) | CTSASUCNR1KMT2ASMN1; SMN2PIM1 | |
| SCHEMBL20546125 | 0.83 | PIM2 (0.50) | CTSASUCNR1KMT2ASMN1; SMN2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615514-B1 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS INC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | ITGB3, ITGA1, ITGB5 | CTSA 2240/4885KMO 3946/4885CTSL 2956/4885 |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | ITGB3, ITGA1, ITGB5 | CTSA 2240/4885KMO 3946/4885CTSL 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.